Physicians' Opinions About Responsibility for Patient Out-of-Pocket Costs and Formulary Prescribing in Two Midwestern States

BACKGROUND Multi-tier copayment designs in pharmacy benefit plans are intended to steer patients and prescribers to preferred drug therapies that have lower out-of-pocket costs for patients. OBJECTIVE To describe and assess physicians' prescribing experiences and opinions in a multi-tier, primarily 3-tier formulary environment in 2 Midwestern states. METHODS This was a cross-sectional survey of physicians practicing in either Minnesota or North Dakota. A packet consisting of a survey instrument, a cover letter, and a postage-paid return envelope was mailed to a random sample of 690 physician members of the Minnesota Medical Association (n = 460, 5.1% of members) or the North Dakota Medical Association (n = 230, 25.6% of members). Surveys were mailed between March and May 2006. Nonresponders were mailed up to 2 additional surveys. Survey items included practice specialty, sources used to obtain drug information, perceived importance of cost containment actions (e.g., prescribing drug with lowest total cost, prescribing drug that minimizes patient out-of-pocket cost), and how often the physician was personally aware of the following when writing a prescription: identity of the patient's insurer, patient's pharmacy benefit structure, preferred medications on the insurer's formulary, patient's copayment (out-of-pocket cost) responsibility, and list price of the medication. RESULTS The survey response rate was 49.8% (296 of 594). The results were as follows: 93.5% of respondents agreed that it was important to prescribe the drug that would minimize the patient's out-of-pocket costs, 73.2% agreed that it was important to discuss out-of-pocket medication costs with patients, 81.8% of respondents agreed that it was important to prescribe the drug with the lowest total costs, and 33.3% of respondents believed that it was their responsibility to prescribe a preferred (formulary) medication. According to the survey, 61.6% of respondents were rarely or never aware of their patient's copayment amounts, and 42.4% were rarely or never aware of the list price of the medication. Physician specialty was associated with the awareness of the identity of the patient's insurer (generalists, 41.1% vs. specialists, 19.2%; P = 0.001) and use of personal digital assistant (PDA) when prescribing (generalists, 38.9% vs. specialists, 21.1%; P = 0.005). CONCLUSION Physicians who responded to this survey believed that it was important to prescribe drugs that would minimize patients' prescription copayments, but they were often unaware of the preferred medications on the formulary, the patients' copayment amounts, or the price of the drugs prescribed.

[1]  B. Motheral,et al.  The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation. , 1999, The American journal of managed care.

[2]  K. Fairman The Future of Prescription Drug Cost-Sharing: Real Progress or Dropped Opportunity? , 2008, Journal of managed care pharmacy : JMCP.

[3]  K. Farris,et al.  Outcomes-based pharmacist reimbursement: reimbursing pharmacists for cognitive services part 1. , 2002, Journal of managed care pharmacy : JMCP.

[4]  J. Avorn Balancing the cost and value of medications: the dilemma facing clinicians. , 2002, PharmacoEconomics.

[5]  B. Dowd,et al.  Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. , 2007, Journal of managed care pharmacy : JMCP.

[6]  Dana P Goldman,et al.  Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. , 2006, The American journal of managed care.

[7]  Thomas Pasko,et al.  Physician Characteristics and Distribution in the Us: 1999 , 1998 .

[8]  MS Dr. G. Caleb Alexander MD,et al.  Barriers to patient-physician communication about out-of-pocket costs , 2007, Journal of general internal medicine.

[9]  B. Motheral,et al.  Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. , 2003, Clinical therapeutics.

[10]  Todd D. Sorensen,et al.  Assessing risk for loss of rural pharmacy services in Minnesota. , 2005, Journal of the American Pharmacists Association : JAPhA.

[11]  Howard C. Anderson,et al.  The North Dakota Telepharmacy Project: Restoring and Retaining Pharmacy Services in Rural Communities , 2004 .

[12]  B. Motheral,et al.  Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization , 2001, Medical care.

[13]  K. Knapp,et al.  Availability of primary care providers and pharmacists in the United States. , 1999, Journal of the American Pharmaceutical Association.

[14]  T. Rector,et al.  Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations. , 2000, JAMA.

[15]  L. Casalino,et al.  Patient-physician communication about out-of-pocket costs. , 2003, JAMA.

[16]  D. Taira,et al.  Alternate Financial Incentives in Multi-tiered Formulary Systems to Improve Accountability for Outcomes , 2003, Journal of managed care pharmacy : JMCP.

[17]  David O Meltzer,et al.  Physician strategies to reduce patients' out-of-pocket prescription costs. , 2005, Archives of internal medicine.

[18]  R. Epstein,et al.  The effect of incentive-based formularies on prescription-drug utilization and spending. , 2003, The New England journal of medicine.

[19]  K. Covinsky,et al.  Self-restriction of medications due to cost in seniors without prescription coverage , 2001, Journal of General Internal Medicine.

[20]  R. Kravitz,et al.  Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most? , 2006, The American journal of managed care.

[21]  Steven M. Asch,et al.  The effect of pharmacy benefit design on patient-physician communication about costs , 2006, Journal of General Internal Medicine.

[22]  R. Kravitz,et al.  Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. , 2005, The American journal of managed care.

[23]  Susan L Ettner,et al.  The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. , 2006, Archives of internal medicine.

[24]  R. Kravitz,et al.  Physicians’ Perceived Knowledge of and Responsibility for Managing Patients’ Out-of-Pocket Costs for Prescription Drugs , 2006, The Annals of pharmacotherapy.